Eli Lilly to invest over $1B in India to expand manufacturing capacity

Eli Lilly (LLY.N) will invest more than $1 billion in India in the coming years to boost manufacturing and supply through local drugmakers, the company said on Monday, as it seeks to tap into skilled workforce to bolster its global manufacturing expansion.

The collaborations aim to increase the availability of Lilly's key drugs, including those for obesity, diabetes, Alzheimer's, cancer and autoimmune conditions, the company said.

Lilly's investment plans in India come at a time when global drugmakers are rushing to bolster U.S. manufacturing capacity after the Trump administration imposed a 100% tariff on imported branded and patented drugs from Oct. 1.

Last month, Lilly announced a $5 billion investment in a new facility in Virginia, part of a $27 billion expansion plan to build four new U.S. plants over the next five years.

Read more from Reuters.